Categories: News

Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th

– CEO Remi Barbier to Discuss Q1 2022 Clinical and Corporate Updates –

– Stakeholders Are Invited to Submit Questions via Email –

– Fireside Chat Will Be Open to The Public via Webcast –

AUSTIN, Texas, March 30, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that Remi Barbier, its President & CEO, will discuss clinical and corporate updates for Q1 2022 in a fireside chat and presentation on Tuesday, April 5, 2022, at 9am Eastern time.

This event, open to the public, will be conducted exclusively via webcast.

Stakeholders are encouraged to submit questions or comments for management’s consideration. Please email in advance of the event your questions and full name to: SAVAquestionsQ1@CassavaSciences.com

Management may not be able to address all comments or questions due to SEC Regulation Fair Disclosure (FD), limits around legal disclosures, time constraints or other limitations.

Detailed instructions on how to attend the webcast will be made available prior to the event. A webcast of Cassava Sciences’ fireside chat will be available for replay following the event on www.CassavaSciences.com in the ‘Investors’ section.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. We are currently testing simufilam, our lead drug candidate for the proposed treatment of Alzheimer’s disease, in Phase 3 clinical studies under Special Protocol Assessments from the FDA. Simufilam is also being tested in an open-label study and a randomized, double-blind, placebo-controlled Cognition Maintenance Study in patients with Alzheimer’s disease.

For more information, please visit: https://www.CassavaSciences.com  

For More Information Contact:
Eric Schoen, Chief Financial Officer
ESchoen@CassavaSciences.com
(512) 501-2450

Staff

Recent Posts

Genflow Biosciences PLC Announces Strengthening of Pre-Clinical Efforts

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION…

1 min ago

The Mount Kisco Surgery Center LLC d/b/a The Ambulatory Surgery Center of Westchester -Notice of Data Security Incident

MOUNT KISCO, N.Y., June 26, 2024 /PRNewswire/ -- The Mount Kisco Surgery Center LLC d/b/a…

8 hours ago

Ontinue Recognized as Finalist of 2024 Healthcare and Life Sciences Microsoft Partner of the Year

REDWOOD CITY, Calif., June 26, 2024 /PRNewswire/ -- Ontinue, a leading provider of AI-powered managed extended…

8 hours ago

American College of Radiology Launches First Medical Practice Artificial Intelligence Quality Assurance Program

ARCH-AI Can Help Radiology Sites Safely and Effectively Implement AI in Daily Practice RESTON, Va.,…

8 hours ago

Rep. Hillary Scholten and the National Blood Clot Alliance Award Corewell Health Butterworth Hospital as a VTE Center of Excellence

GRAND RAPIDS, Mich., June 26, 2024 /PRNewswire/ -- On June 24, 2024, Rep. Hillary Scholten (MI-03) joined…

8 hours ago